Clinical study of intravitreal ranibizumab as early treatment for macular edema result by retinal vein occlusion

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-16009509

Enrollment

Unknown

Registered

2016-10-20

Start date

2017-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion

Interventions

case series: intravitreal ranibizumab

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with retinal vein occlusion; 2. Informed and voluntary to participate in the clinical trial.

Exclusion criteria

Exclusion criteria: 1. With other ocular diseases; 2. Subjects want to withdraw from the trial anytime.

Design outcomes

Primary

Measure	Time frame
visual acurity;macular edema;	—

Countries

China

Contacts

Public ContactJun Zeng

Department of Ophthalmology of The Second Xiangya Hospital, Central South University

zengjun607@qq.com+86 13017193119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026